Mezzion Pharma KRX:140410KOSDAQ

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

1. 1
   Mezione transfers udenafil Australian patent rights for 5.37 billion won

   2 outlets · 2 articlesFirst report Nov 4 13:59 리드경제
2. 2
   Mezione pursues Phase 2 skip for polycystic kidney disease, seeks FDA consultation on Phase 3 design

   1 outlets · 1 articlesFirst report Nov 9 07:26 메디코파마Regulatory approval
3. 3
   Mezione transfers udenafil Australian patent rights for 5.364 billion won, equivalent to 67.83% of last year's sales

   1 outlets · 1 articlesFirst report Nov 4 14:07 CBC뉴스

• Nov 907:26
  MajorMezione pursues Phase 2 skip for polycystic kidney disease, seeks FDA consultation on Phase 3 design

  메디코파마Regulatory approval
• Nov 414:07
  BreakingMezione transfers udenafil Australian patent rights for 5.364 billion won, equivalent to 67.83% of last year's sales

  CBC뉴스
• Nov 413:59
  Mezione transfers udenafil Australian patent rights for 5.37 billion won

  리드경제

  1 more on this story · 1 outlets

  • Mezione transfers udenafil Australian patent rights for 4 million dollarsPRESS9 · Nov 4 16:13
• Oct 507:32
  Mezione's 170 billion won overhang from BRV contract termination highlighted, stock down about 4x relative to investment

  메디코파마
• Oct 308:33
  Mezione spins off chronic kidney disease biotech entity, eyeing global M&A

  리드경제
• Sep 2611:02
  Mezione sets separate pricing on chronic kidney disease drug, establishes US subsidiary eyeing M&A

  이데일리

  1 more on this story · 1 outlets

  • Mezione sets separate pricing on chronic kidney disease drug, establishes US subsidiary eyeing M&A이데일리 · Sep 26 11:01